Metrics as of 10/15/2026, 10:45 AM (Berlin time), refresh in progress.
NeuroSense Therapeutics Stock
NeuroSense Therapeutics Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Alon Ben-Noon
- Employees
- 17
- Market cap
- $6 M
- IPO
- 09/12/2021
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has…
NeuroSense Therapeutics stock: price history
1D
-12.3%
1W
-19.9%
1M
-55.7%
6M
-79.0%
YTD
-80.1%
1Y
-87.7%
2Y
-86.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~16% stronger price swings than usual
Ask the agents about NeuroSense Therapeutics
Analyst assessment of NeuroSense Therapeutics
0
STRONG BUY
2
BUY
1
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 28/09/2026
NeuroSense Therapeutics stock metrics
P/E
-0.43
P/B
-2.51
EV/EBITDA
-0.67
RETURN ON EQUITY
205.6%
NET MARGIN
0.0%
DEBT/EQUITY
-0.11
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
62.9%
FLOAT SHARES
1,193,534
AVG. DAILY VOLUME (30D)
29,713
Insider transactions (SEC)
Eisenberg Or
Ben-Noon Alon
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about NeuroSense Therapeutics stock
What does NeuroSense Therapeutics do?
NeuroSense Therapeutics Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Alon Ben-Noon, the company employs around 17 people.
The IPO was on 09/12/2021; the stock trades on NASDAQ under the ticker NRSN.
What do analysts say about NeuroSense Therapeutics stock?
3 analysts rate the stock, the consensus is Buy (as of 28/09/2026).
This is an external assessment, not a statement by Market Jury.
When does NeuroSense Therapeutics report next?
Around past earnings, price swings were roughly 16% stronger than usual.
Does NeuroSense Therapeutics pay a dividend?
No, NeuroSense Therapeutics currently does not pay a dividend.
Which stocks are comparable to NeuroSense Therapeutics?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get NeuroSense Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess NeuroSense Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.